NCT04965597 2026-03-09
Treosulfan-Based Conditioning Regimen Before a Blood or Bone Marrow Transplant for the Treatment of Bone Marrow Failure Diseases (BMT CTN 1904)
Fred Hutchinson Cancer Center
Phase 2 Completed
Clinical Trials
12 trialsNCT03961919 2023-11-18
FLAT-Auto
IRCCS San Raffaele
Phase 2 Completed
NCT01063647 2023-11-03
Dose-range Finding Treosulfan-based Conditioning
medac GmbH
Phase 1/2 Completed
NCT00796068 2023-02-17
Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematological Cancer Who Are Undergoing Umbilical Cord Blood Transplant
Fred Hutchinson Cancer Center
Phase 2 Completed
NCT00822393 2020-07-30
Clinical Phase III Trial Treosulfan-based Conditioning Versus Reduced-intensity Conditioning (RIC)
medac GmbH
Phase 3 Completed
NCT02333058 2020-05-04
Treosulfan-based Conditioning in Paediatric Patients With Haematological Malignancies
medac GmbH
Phase 2 Completed
NCT00987636 2019-10-22
EWING2008
University Hospital Muenster
Phase 3 Completed
NCT00491634 2015-12-02
Treosulfan-based Conditioning for Transplantation in AML/MDS
Sheba Medical Center
Phase 2 Completed
NCT00170690 2013-06-03
Preference Study With Elderly Patients Recurrent Ovarian Cancer
North Eastern German Society of Gynaecological Oncology
Phase 3 Completed
NCT00253513 2012-06-01
Treosulfan and Fludarabine in Treating Younger Patients Who Are Undergoing a Donor Stem Cell Transplant for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome
OHSU Knight Cancer Institute
Phase 1/2 Completed
NCT01063660 2010-02-05
Treosulfan Based Conditioning Acute Myeloid Leukaemia (AML)
medac GmbH
Phase 2 Completed
NCT01062490 2010-02-04
Treosulfan Based Conditioning Myelodysplastic Syndrome (MDS)
medac GmbH
Phase 2 Completed